[{"id":"4bf8a0e4-ad61-4bd3-8b19-15b271d96a0b","acronym":"D9750C00001","url":"https://clinicaltrials.gov/study/NCT06005493","created_at":"2023-08-22T15:08:52.377Z","updated_at":"2025-02-25T14:10:00.557Z","phase":"Phase 1/2","brief_title":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06005493 - D9750C00001","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive • CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive • CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD5863"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 12/16/2026","primary_completion_date":" 12/16/2026","study_txt":" Completion: 12/16/2026","study_completion_date":" 12/16/2026","last_update_posted":"2025-02-18"},{"id":"56fa4122-48b0-496d-9b08-3036a6a23a21","acronym":"TACTIC-3","url":"https://clinicaltrials.gov/study/NCT05862324","created_at":"2023-05-17T14:05:21.313Z","updated_at":"2025-02-25T14:42:02.177Z","phase":"Phase 1/2","brief_title":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","source_id_and_acronym":"NCT05862324 - TACTIC-3","lead_sponsor":"Triumvira Immunologics, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation","tags":["EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 08/23/2023","start_date":" 08/23/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-14"},{"id":"e5e3ad81-9df9-4560-a791-5e9b3953d9ad","acronym":"KYM901","url":"https://clinicaltrials.gov/study/NCT04805307","created_at":"2021-03-18T11:52:24.597Z","updated_at":"2025-02-25T15:19:03.220Z","phase":"Phase 1","brief_title":"Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901","source_id_and_acronym":"NCT04805307 - KYM901","lead_sponsor":"Keymed Biosciences Co.Ltd","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sonesitatug vedotin (AZD0901)"],"overall_status":"Completed","enrollment":" Enrollment 176","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 04/05/2024","primary_completion_date":" 04/05/2024","study_txt":" Completion: 04/05/2024","study_completion_date":" 04/05/2024","last_update_posted":"2025-02-12"},{"id":"47c94276-aadc-4f56-b0e4-df2a44de0e7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04900818","created_at":"2021-05-25T18:52:39.848Z","updated_at":"2025-02-25T14:16:01.935Z","phase":"Phase 1","brief_title":"Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04900818","lead_sponsor":"I-Mab Biopharma US Limited","biomarkers":" PD-L1 • CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["PD-L1 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • givastomig (TJ-CD4B)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 06/29/2021","start_date":" 06/29/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-01-03"},{"id":"076cd6de-9c13-4f66-953e-ae61920d0ae1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05911217","created_at":"2023-06-20T14:07:52.799Z","updated_at":"2024-07-02T16:35:00.806Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer","source_id_and_acronym":"NCT05911217","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e satricabtagene autoleucel (CT041)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-27"},{"id":"9507ed2f-0466-4ed9-9e93-1955c7856ffd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065710","created_at":"2021-10-04T12:52:58.772Z","updated_at":"2024-07-02T16:35:01.207Z","phase":"Phase 1/2","brief_title":"A Study of ZL-1211 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT05065710","lead_sponsor":"Zai Biopharmaceutical (Suzhou) Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZL-1211"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 01/19/2022","start_date":" 01/19/2022","primary_txt":" Primary completion: 03/09/2024","primary_completion_date":" 03/09/2024","study_txt":" Completion: 04/09/2024","study_completion_date":" 04/09/2024","last_update_posted":"2024-05-24"},{"id":"a07fe804-b24b-42e5-81ce-af1dddb29fdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04400383","created_at":"2021-03-09T08:59:58.256Z","updated_at":"2024-07-02T16:35:00.974Z","phase":"Phase 1","brief_title":"Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors","source_id_and_acronym":"NCT04400383","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • AB011"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 06/04/2020","start_date":" 06/04/2020","primary_txt":" Primary completion: 07/08/2023","primary_completion_date":" 07/08/2023","study_txt":" Completion: 09/28/2023","study_completion_date":" 09/28/2023","last_update_posted":"2024-05-24"},{"id":"2f2a89e1-3f78-4f28-8767-c134a39deb5d","acronym":"ILUSTRO","url":"https://clinicaltrials.gov/study/NCT03505320","created_at":"2021-01-18T17:15:25.042Z","updated_at":"2024-07-02T16:35:04.695Z","phase":"Phase 2","brief_title":"A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma","source_id_and_acronym":"NCT03505320 - ILUSTRO","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" PD-L1 • CLDN18","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • CLDN18.2 expression • CLDN18.2 positive","tags":["PD-L1 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • CLDN18.2 expression • CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab-clzb)"],"overall_status":"Recruiting","enrollment":" Enrollment 143","initiation":"Initiation: 06/29/2018","start_date":" 06/29/2018","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-09"},{"id":"56340f92-11bf-404d-bdf4-c92c67bb6993","acronym":"","url":"https://clinicaltrials.gov/study/NCT05001516","created_at":"2021-08-12T14:54:30.593Z","updated_at":"2024-07-02T16:35:09.043Z","phase":"Phase 1","brief_title":"Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors","source_id_and_acronym":"NCT05001516","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" MSI • CLDN18","pipe":" | ","alterations":" MSI-H/dMMR • CLDN18.2 expression • CLDN18.2 positive","tags":["MSI • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • CLDN18.2 expression • CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tecotabart vedotin (LM-302)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 12/29/2021","start_date":" 12/29/2021","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2024","study_completion_date":" 01/04/2024","last_update_posted":"2024-04-17"},{"id":"577d5037-eb6e-4785-b20b-69876702f3ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT04671875","created_at":"2021-03-09T09:00:11.648Z","updated_at":"2024-07-02T16:35:14.865Z","phase":"Phase 1","brief_title":"A Clinical Study of MIL93 in Solid Tumors.","source_id_and_acronym":"NCT04671875","lead_sponsor":"Beijing Mabworks Biotech Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MIL93"],"overall_status":"Recruiting","enrollment":" Enrollment 228","initiation":"Initiation: 04/21/2021","start_date":" 04/21/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-03-13"},{"id":"6d1b5764-e77a-48d0-bb8b-8c63cc77a81d","acronym":"LB1908-1001","url":"https://clinicaltrials.gov/study/NCT05539430","created_at":"2022-09-14T18:56:15.361Z","updated_at":"2024-07-02T16:35:15.456Z","phase":"Phase 1","brief_title":"Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT05539430 - LB1908-1001","lead_sponsor":"Legend Biotech USA Inc","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LB1908"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-11"},{"id":"c23452ee-9413-4c76-bc52-df1b531d2d45","acronym":"","url":"https://clinicaltrials.gov/study/NCT04581473","created_at":"2021-03-09T09:00:08.732Z","updated_at":"2024-07-02T16:35:16.030Z","phase":"Phase 1/2","brief_title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection","source_id_and_acronym":"NCT04581473","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 expression • CLDN18.2 positive","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • AiTan (rivoceranib) • irinotecan • satricabtagene autoleucel (CT041)"],"overall_status":"Recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2038","study_completion_date":" 06/30/2038","last_update_posted":"2024-03-06"},{"id":"d79eae6c-ee5a-4ce6-8ddc-e1255dc5565e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05639153","created_at":"2022-12-06T15:58:04.640Z","updated_at":"2024-07-02T16:35:22.153Z","phase":"Phase 1","brief_title":"A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05639153","lead_sponsor":"Zhejiang Doer Biologics Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DR30303"],"overall_status":"Recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 05/13/2022","start_date":" 05/13/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-01-25"},{"id":"71a3a4f5-c99c-458e-aa62-fed7409bf1e8","acronym":"ELIMYN18.2","url":"https://clinicaltrials.gov/study/NCT04404595","created_at":"2021-03-09T08:59:58.909Z","updated_at":"2024-07-02T16:35:25.770Z","phase":"Phase 1/2","brief_title":"Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers","source_id_and_acronym":"NCT04404595 - ELIMYN18.2","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e satricabtagene autoleucel (CT041)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2035","study_completion_date":" 09/01/2035","last_update_posted":"2023-12-19"},{"id":"5064553d-e4ed-498f-bc5e-f6c9536a84d7","acronym":"CSG-1906-101","url":"https://clinicaltrials.gov/study/NCT05857332","created_at":"2023-05-12T17:05:01.178Z","updated_at":"2024-07-02T16:35:28.556Z","phase":"Phase 1","brief_title":"SG1906 for CLDN18.2-Positive Solid Tumors","source_id_and_acronym":"NCT05857332 - CSG-1906-101","lead_sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SG1906"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 08/30/2025","study_completion_date":" 08/30/2025","last_update_posted":"2023-11-21"},{"id":"c29522a3-7871-451f-9b15-79b2e1027e0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06084286","created_at":"2023-10-16T15:12:50.114Z","updated_at":"2024-07-02T16:35:33.444Z","phase":"Phase 1","brief_title":"Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors","source_id_and_acronym":"NCT06084286","lead_sponsor":"Sichuan University","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 10/30/2026","primary_completion_date":" 10/30/2026","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2023-10-16"},{"id":"96bebf64-22cc-44fe-8eb7-2b3fcb1d55b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05934331","created_at":"2023-07-06T16:10:33.332Z","updated_at":"2024-07-02T16:35:34.327Z","phase":"Phase 2","brief_title":"A LM-302 Combined With Toripalimab Phase II Study","source_id_and_acronym":"NCT05934331","lead_sponsor":"LaNova Medicines Zhejiang Co., Ltd.","biomarkers":" PD-L1 • CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["PD-L1 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • tecotabart vedotin (LM-302)"],"overall_status":"Recruiting","enrollment":" Enrollment 276","initiation":"Initiation: 07/27/2023","start_date":" 07/27/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-10-06"},{"id":"ce53abad-b3e8-4c4b-9177-ef32c0764dd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05946226","created_at":"2023-07-14T18:09:04.276Z","updated_at":"2024-07-02T16:35:35.396Z","phase":"Phase 1","brief_title":"A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors","source_id_and_acronym":"NCT05946226","lead_sponsor":"Suzhou Immunofoco Biotechnology Co., Ltd","biomarkers":" CLDN18 • IL6 • IL2 • IL10","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18 • IL6 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IMC001 • IMC002 • danburstotug (IMC-001)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-28"},{"id":"d373713b-7551-40ea-9bb5-fad8b89a9bc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06027346","created_at":"2023-09-07T16:09:46.120Z","updated_at":"2024-07-02T16:35:37.753Z","phase":"Phase 1","brief_title":"A Study of Bio-008 in Subjects With Advanced or Metastatic Solid Tumours","source_id_and_acronym":"NCT06027346","lead_sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression • CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression • CLDN18.2 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/17/2023","start_date":" 07/17/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-09-07"},{"id":"ccc06936-f76a-49da-b8fa-d22d094886ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT05199519","created_at":"2022-01-20T14:53:32.658Z","updated_at":"2024-07-02T16:35:47.265Z","phase":"Phase 1","brief_title":"Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345","source_id_and_acronym":"NCT05199519","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IBI-345"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 12/13/2021","start_date":" 12/13/2021","primary_txt":" Primary completion: 10/29/2022","primary_completion_date":" 10/29/2022","study_txt":" Completion: 01/19/2023","study_completion_date":" 01/19/2023","last_update_posted":"2023-05-24"},{"id":"3b6ac439-85dd-4ce9-8f0d-f7d06cac5169","acronym":"","url":"https://clinicaltrials.gov/study/NCT05839106","created_at":"2023-05-03T15:04:23.524Z","updated_at":"2025-02-25T16:27:19.857Z","phase":"Phase 1/2","brief_title":"Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05839106","lead_sponsor":"Biotheus Inc.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PM1032"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/08/2022","start_date":" 07/08/2022","primary_txt":" Primary completion: 04/10/2025","primary_completion_date":" 04/10/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-05-05"},{"id":"4e8933c7-95c5-47ee-93c6-8de36a6aa90b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05837299","created_at":"2023-05-01T14:04:02.008Z","updated_at":"2024-07-02T16:35:49.216Z","phase":"Phase 1","brief_title":"A Study of IMC008 for Advanced Solid Tumors","source_id_and_acronym":"NCT05837299","lead_sponsor":"Changhai Hospital","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IMC008"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/02/2023","start_date":" 04/02/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2023-05-01"},{"id":"8f9d762e-021e-4c20-8f14-6257969fc846","acronym":"","url":"https://clinicaltrials.gov/study/NCT05632939","created_at":"2022-12-01T15:57:05.783Z","updated_at":"2024-07-02T16:35:55.253Z","phase":"Phase 1/2","brief_title":"ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable G/GEJ Cancer.","source_id_and_acronym":"NCT05632939","lead_sponsor":"AskGene Pharma, Inc.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • capecitabine • oxaliplatin • ASKB589"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 02/10/2023","start_date":" 02/10/2023","primary_txt":" Primary completion: 02/10/2025","primary_completion_date":" 02/10/2025","study_txt":" Completion: 02/10/2026","study_completion_date":" 02/10/2026","last_update_posted":"2023-02-17"},{"id":"1a820df7-ed63-4b53-befa-97ea8dbdf065","acronym":"","url":"https://clinicaltrials.gov/study/NCT04632108","created_at":"2021-01-19T20:36:42.292Z","updated_at":"2024-07-02T16:35:55.308Z","phase":"Phase 1/2","brief_title":"A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04632108","lead_sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASKB589"],"overall_status":"Recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 01/28/2021","start_date":" 01/28/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-02-16"}]